Publications

Goyak KO, Sarang SS, Franzen A, Borghoff SJ, Ryman-Rasumssen JP. 2022. Adverse outcome pathway (AOP): α2u-globulin nephropathy and kidney tumors in male rats. Crit Rev Toxicol 52(5):345-357; doi: 10.1080/10408444.2022.2082269. PMID: 35862579.

Henderson RG, Nguyen H. 2022. Pathways to the US supplement market: New dietary ingredient notification and Generally Recognized as Safe determination. Chapter 19 in: Ruthsatz M, Wong AW (eds), Nutrition, Health, and Disease: Regulatory Policy Matters. Regulatory Affairs Professionals Society (RAPS), online store.

Knotts T, Diokno R, Husfeld C, Weinberger D, Mease K, Wollowitz S, Kramer S, Donovan J. Vocacapsaicin (formerly CA-008): A water-soluble prodrug for rapid release of capsaicin for the treatment of postsurgical pain. Presentation to American Association of Pharmaceutical Scientists, AAPS PHARMSCI 360, Boston, MA, October 2022.

Suh M, Cloud M, Balasubramanian A, Movva N, Fryzek J, Cohen S. 2022. A systematic literature review (SLR) of MTAP deletions in multiple solid and hematologic cancers. PROSPERO 2022 CRD42022354037.

Lynch HN, Lauer DJ, Thompson WJ, Leleck O, Freid RD, Collins J, Chen K, et al. 2022. Systematic review of the scientific evidence of the pulmonary carcinogenicity of talc. Front Public Health 10:989111; doi: 10.3389/fpubh.2022.989111.

Danese MD, Schenfeld J, Shaw J, Gawade P, Balasubramanian A, Kelsh M, et al. 2022. Association between granulocyte colony-stimulating factor (G-CSF) use and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) among elderly patients with breast, lung, or prostate cancer.  Adv Ther 39(6):2778–2795. doi:10.1007/s12325-022-02141-1.

Schenfeld J, Gong T, Henry D, Kelsh M, Gawade P, Peng Y, Bradbury BD, Li S. 2022. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 30(7):6327–6338. doi: 10.1007/s00520-022-06967-x.

Hulsey A, Cekola P, Henrikson A, Reichert H, Cohen SS, Torres KA. 2022. Growth and tolerance with an amino acid based enteral formula: A two-year retrospective study from a children’s rehabilitation hospital. J Clin Nutr Dietet 8(8):181.

Klosterbuer A, Cekola P, Neutel JM, Jiang X, Cohen SS, Torres KA. Diabetes specific ONS led to a blunted postprandial glucose response & a 26% reduction in peak blood glucose levels compared to a standard ONS. Presented at FNCE 2022 Food & Nutrition Conference & Expo, Orlando, FL, October 2022.

Lefever TW, Schwotzer D, Bonn-Miller MO, McDonald J, Henderson RG, Trexler KR. Novel data update on oral toxicity of phytocannabinoids in rats after 14-days repeated dosing. Carolina Cannabinoid Collaborative (CCC) Conference, Greenville, NC, November 2022.

Czerkies L, Reichert H, Cohen S. Factors affecting weight gain in infant formula growth studies. Presented at Nutrition&Growth, virtual conference, 2022.

Bylsma LC, Movva N, Fryzek JP, Rege S, Lewis RJ. 2022. Scoping review of employer-led research using employee health claims data. Open Science Framework.

Reichert H, Suh M, Jiang X, Movva N, Bylsma LC, Fryzek JP, Nelson CB. 2022. Mortality associated with respiratory syncytial virus, bronchiolitis, and influenza among infants in the United States: A birth cohort study from 1998 to 2018. J Infect Dis 226(Suppl 2):S246–S254.

Bylsma LC, Suh M, Movva N, Fryzek JP, Nelson CB. 2022. Mortality among United States infants and children under 5 years of age with respiratory syncytial virus and bronchiolitis: A systematic literature review. J Infect Dis 226(Suppl 2):S267–S281.

Movva N, Suh M, Bylsma LC, Fryzek JP, Nelson CB. 2022. Systematic literature review of respiratory syncytial virus laboratory testing practices and incidence in United States infants and children <5 years of age. J Infect Dis 226(Suppl 2):S213–S224.

Suh M, Movva N, Bylsma LC, Fryzek JP, Nelson CB. 2022. A systematic literature review of the burden of respiratory syncytial virus disease and health care utilization among United States infants younger than 1 year. J Infect Dis 226(Suppl 2):S195–S212.

Suh M, Movva N, Jiang X, Reichert H, Bylsma LC, Fryzek JP, Nelson CB. 2022. Respiratory syncytial virus burden and healthcare utilization in United States infants, <1 year of age: Study of nationally representative databases, 2011–2019. J Infect Dis 226(Suppl 2):S184–S194.

Movva N, Suh M, Reichert H, Hitze B, Sendak MP, Wolf Z, et al. 2022. Respiratory syncytial virus during the COVID-19 pandemic compared to historic levels: A retrospective cohort study of a health system. J Infect Dis 226(Suppl 2):S175–S183.

Suh M, Movva N, Jiang X, Bylsma LC, Reichert H, Fryzek JP, Nelson CB. 2022. Respiratory syncytial virus (RSV) is the leading cause of United States infant hospitalizations 2009–2019: A study of the National (Nationwide) Inpatient Sample. J Infect Dis 226(Suppl 2):S154–S163.